Obinutuzumab-Bendamustine Produces High Response Rates in Chinese Patients With Indolent B-Cell Lymphomas

Induction therapy with obinutuzumab (Gazyva; Genentech) plus bendamustine followed by obinutuzumab maintenance produced high response rates in Chinese patients with newly diagnosed indolent B-cell lymphomas, according to findings from a prospective, multicenter, open-label study published in MedScience.¹

The results expand the evidence supporting this combination beyond follicular lymphoma (FL), but the study’s single-arm design and median follow-up of 13.1 months prevent direct comparisons with other frontline regimens.

Study Evaluates Multiple Indolent Lymphoma Subtypes

Indolent B-cell non-Hodgkin lymphomas encompass a heterogeneous group of malignancies that generally progress slowly but frequently follow a relapsing course. The new study included patients with FL, marginal zone lymphoma (MZL), Waldenström macroglobulinemia (WM), hairy cell leukemia variant (HCL-v), and unclassified B-cell lymphoproliferative disorder (BCLPD-U).¹

The researchers enrolled 220 adults with newly diagnosed disease across 8 centers in China. Of these patients, 149 had FL and 71 had a non-FL subtype. A total of 210 patients completed at least 3 treatment cycles.¹

Patients received 6 induction cycles of obinutuzumab plus bendamustine. Those who achieved at least a partial response proceeded to obinutuzumab maintenance for 2 years. The primary end point was overall response rate (ORR), with complete response rate, duration of response, progression-free survival (PFS), overall survival (OS), and safety evaluated as secondary end points.¹

Obinutuzumab is a glycoengineered type 2 anti-CD20 monoclonal antibody designed to enhance antibody-dependent cellular cytotoxicity and direct cell death. In the US, it is approved with chemotherapy followed by obinutuzumab maintenance for adults with previously untreated stage 2 bulky, stage 3, or stage 4 FL.²

Responses Were High Across Disease Subtypes

At the 13.1-month median follow-up, the ORR was 96.6% among patients with FL. Response rates were also high in the less common disease groups, reaching 100% in both MZL and HCL-v, 92.9% in WM, and 88.9% in BCLPD-U.¹

The aggregate FL and non-FL populations had comparable ORRs. However, patients with FL achieved a significantly higher complete response rate than those with non-FL disease, at 92.4% and 78.5%, respectively (P = .004).¹

The median duration of response was 16.7 months in the FL cohort and had not been reached in the non-FL cohort. Median PFS and OS were not reached in any subgroup. Despite a deeper response in FL, the non-FL population had significantly longer PFS at the data cutoff (P = .020).¹

Longer follow-up will be necessary to determine whether this difference persists.

These findings complement results from the phase 3 GALLIUM trial (NCT01332968), which established a PFS advantage for obinutuzumab-based immunochemotherapy over rituximab-based immunochemotherapy in previously untreated FL. The final GALLIUM analysis showed that this PFS benefit remained evident after approximately 8 years of follow-up, although not significant.^3,4

The new study should not be interpreted as demonstrating that Chinese patients benefit more from the regimen than Western populations. Its high complete response rate is notable, but differences in patient selection, disease biology, response assessment, and follow-up make cross-trial comparisons unreliable.

Infection Monitoring Remains a Pharmacy Priority

Treatment-emergent adverse events were reported in 42 patients. These events occurred more often in the non-FL group than in the FL group, at 26.8% and 15.4%, respectively (P = .046). Infections accounted for an important portion of this difference, occurring in 18.3% of patients with non-FL disease compared with 6.0% of those with FL (P = .005).¹

These findings reinforce the need for pharmacists to monitor blood counts, infection symptoms, and cumulative immunosuppression throughout induction and maintenance. Bendamustine can produce prolonged lymphocyte depletion, while obinutuzumab carries risks that include neutropenia, serious infections, infusion-related reactions, hepatitis B virus reactivation, and progressive multifocal leukoencephalopathy.²

Before obinutuzumab treatment, patients should be screened for hepatitis B virus infection. Pharmacists can also help coordinate infusion premedication, tumor lysis syndrome prophylaxis, laboratory monitoring, antimicrobial prophylaxis when clinically appropriate, and counseling on when to report infection symptoms.²

Promising Findings Require Longer Comparative Follow-Up

This study provides valuable prospective evidence for obinutuzumab plus bendamustine in a Chinese population and includes several uncommon lymphoma subtypes that are often underrepresented in large trials. However, the small subtype cohorts, lack of randomization, limited genomic characterization, and immature survival data restrict the strength of its conclusions.

Future studies should determine whether the high response rates translate into durable disease control and whether biomarkers can identify patients most likely to benefit without excessive immunosuppression. For now, the findings support the regimen’s activity while emphasizing individualized treatment selection and proactive infection management.

REFERENCES

1. Yan Y, Hu X, Sun X, et al. Obinutuzumab plus bendamustine as first-line therapy for indolent B-cell lymphomas: a prospective multicenter open-label study. MedScience. Published online June 2, 2026. doi:10.1007/s11684-026-1200-8.

2. Gazyva (obinutuzumab) injection. Prescribing information. Genentech, Inc. Accessed September 4, 2026. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=df12ceb2-5b4b-4ab5-a317-2a36bf2a3cda&audience=consumer

3. Marcus R, Davies A, Ando K, et al. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. N Engl J Med. 2017;377(14):1331-1344. doi:10.1056/NEJMoa1614598

4, Townsend W, Hiddemann W, Buske C, et al. Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study. Hemasphere. 2023;7(7):e919. Published 2023 Jun 30. doi:10.1097/HS9.0000000000000919

5. Sehn LH, Chua N, Mayer J, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 2016;17(8):1081-1093. doi:10.1016/S1470-2045(16)30097-3